Hainan Shuangcheng Pharmaceuticals002693.SZValuation Analysis

As of Oct 19, 2026, Hainan Shuangcheng Pharmaceuticals (002693.SZ) trades at a P/E of 76.00x, P/B of 9.20x, P/S of 16.70x, and a dividend yield of 0.00%.
Longitudinal percentile comparison: P/E sits at the 13th percentile over the trailing 10Y window (vs. 25th percentile over 3Y); P/B sits at the 93rd percentile over the trailing 10Y window (vs. 77th percentile over 3Y); P/S sits at the 80th percentile over the trailing 10Y window (vs. 60th percentile over 3Y).
Cross-sectional valuation: its P/E ranks at the 75th percentile within its industry and the 73rd percentile across the broader market.
Shareholder return highlight: Total Shareholder Yield is 0.00%; its historical percentile over the trailing long-term window is still accumulating data.
Notably, P/E and P/B aren't telling quite the same story, 79.7 points apart — worth checking the full percentile matrix on this page for the complete picture. Its P/E percentile is roughly the same whether measured against the industry or the broader market. Shareholder returns here are driven almost entirely by cash dividends, with minimal contribution from buybacks. Hainan Shuangcheng Pharmaceuticals operates in the Medicine sector. Data refreshes weekly and is for reference only, not investment advice.